The Court may soon allow future lawsuits over Ozempic, Wegovy, Mounjaro and other GLP-1s to be brought using a Short Form Complaint, adopting allegations from the MDL Master Complaint.
Amid increasing popularity of Ozempic, Wegovy and other GLP-1 drugs, researchers indicate that fewer patients are considering weight loss surgery.
New GLP-1 warnings will urge users to inform their doctors before surgery if they are taking the diabetes and weight loss drugs.
Court will examine general causation, along with other “cross cutting” issues, before selecting any individual Ozempic gastroparesis lawsuits for trial workup.
Researchers have found that users of Ozempic, Mounjaro and similar drugs are less likely to experience opioid overdoses or alcoholism.
Lawsuit indicates that the gastroparesis diagnosis from Ozempic was confirmed after plaintiff underwent a gastric emptying test, which is evidence not present in many other claims in the litigation.
Inadequate bowel prep due to side effects of Ozempic and Mounjaro carries significant risk of missed lesions, canceled procedures and other complications.
Novo Nordisk allegedly knew for years about the risk that Ozempic and Rybelsus may cause ileus and other severe gastrointestinal side effects, but failed to warn doctors or patients.
Side effects of Mounjaro caused cyclical vomiting that required emergency medical treatment, lawsuit claims.
Kentucky woman claims Ozempic caused stomach paralysis, which resulted in the need for emergency medical treatment and left her with permanent injuries.
